Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2026-03-16 Audit Report / Informat…
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive financial report titled '감사보고서' (Audit Report) for Celltrion Pharm, covering the fiscal year 2025. It includes the independent auditor's report, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes. While it contains an audit report, the inclusion of the full set of financial statements and notes for the fiscal year classifies it as an Annual Report (10-K) equivalent in the context of Korean corporate filings. FY 2025
2026-03-16 Korean
감사보고서제출
Audit Report / Information Classification · 97% confidence The document is a regulatory filing from Celltrion Pharm titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion, key financial data (assets, liabilities, revenue, profit), and auditor information. While it contains financial data, it is a formal notification of the submission of the audit report to the regulatory body, rather than the full annual report or a standalone audit report document itself. Under the 'Menu vs Meal' rule, this is a notification of a report filing. FY 2025
2026-03-16 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Audit Report / Information Classification · 95% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Celltrion Pharm. It details intra-group transactions, shareholding structures, and governance-related information (ESG) as required by Korean fair trade regulations. Since it does not fit into specific categories like financial reports, earnings releases, or shareholder meeting materials, and serves as a mandatory regulatory disclosure regarding corporate group status, it is best classified as a Regulatory Filing (RNS). Q1 2024
2026-02-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 6.1' report) used to disclose insider trading or changes in share ownership by company directors and executives. This aligns perfectly with the 'Director's Dealing' (DIRS) category.
2026-02-26 Korean
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure regarding payment methods, payment periods, and dispute resolution mechanisms under the Fair Transactions in Subcontracting Act (South Korea). It is a specific compliance filing required by law for corporate transparency. Since it does not fit into categories like financial reports, earnings releases, or shareholder communications, it falls under the 'Regulatory Filings' category.
2026-02-19 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Celltrion Pharm. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as the approval of financial statements, election of directors, and other corporate governance matters. It also includes detailed management information, board activity reports, and financial statements (balance sheet, income statement) as part of the proxy materials provided to shareholders for the meeting. This document is a classic Proxy Solicitation & Information Statement (PSI) used to inform shareholders and request their votes for the AGM.
2026-02-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.